1982 Volume 56 Issue 4 Pages 294-310
The clinical efficacy and safety of cefadroxil (CDX) and cephalexin (CEX) were evaluated in patients with scarlet fever using a double blind clinical trial.
1) Patients weighing less than 20 kg were administered 600 mg of CDX or 800 mg of CEX. Patients weighing more than 20 kg and less than 30 kg were administered 900 mg of CDX or 1200 mg of CEX. CDX was administered orally 3 times a day for 7 days, while CEX was administered orally 4 times a day for 7 days.
2) A total of 336 patients were treated. Clinical efficacy was examined with 158 patients receiving CDX and 161 patients receiving CEX.
3) There was no statistically significant difference between CDX and CEX in overall efficacy and utility.
4) Patients with disappearance of streptococci of CDX group were more than those of CEX group, but no statistically significant difference was observed between 2 drugs.
5) There was no statistically significant difference between 2 drugs in efficacy on fever, exanthema, pharyngeal redness and pharyngeal streptococci.
6) Adverse reactions were reported in 1 patient receiving CDX and 3 patients receiving CEX. There was no statistically significant difference between 2 drugs.
